신장암 환자에서 Pazopanib을 사용한 후 발생한 심부전 1예

• Published in: The Korean journal of medicine pp. 330 - 333
• Main Authors: 이송이, 임병훈, 김영준, 강상우, 박철, 송주흥, 안선호
• Format: Journal Article
• Language: Korean
• Published: 대한내과학회 01.04.2016
• Subjects: 내과학
• ISSN: 1738-9364; 2289-0769
• DOI: 10.3904/kjm.2016.90.4.330

신세포암은 신장암중에서 가장 흔한 종류의 암으로 진단당시 25-30%의 환자에서 전이성 병변을 가지고 있다[1]. 전이성 신세포암에서 vascular endothelial growth factor receptor (VEGFR) antagonists는 널리 사용되어 오고 있다. 보트리엔트(VotrientTM, Pazopanib)는 VEGFR, platelet-derived growth factor receptors, c-Kit를 표적으로 하는 경구 섭취로 복용할 수 있는표적 치료제이다[2]. A 78-year-old man was diagnosed with renal cell carcinoma, and left nephrectomy was performed. He started pazopanib. One month later, he visited our hospital because of general weakness and dyspnea. His oxygen saturation was low. A chest X-ray showed pulmonary edema and bilateral pleural effusion. An echocardiogram showed a larger left ventricle and lower ejection fraction than observed at the previous examination. The patient discontinued pazopanib and started diuretics and digoxin. His symptoms improved and a follow-up X-ray showed improvement in the pulmonary edema with bilateral pleural effusion. KCI Citation Count: 0